Hunan Jingfeng Pharmaceutical Co

Hunan Jingfeng Pharmaceutical Co CROIC

The Cash Return on Invested Capital (CROIC) of Hunan Jingfeng Pharmaceutical Co (000908.SZ) as of Oct 21, 2026 is 236.59 %. In the previous year, Cash Return on Invested Capital (CROIC) was -2.47 % — a change of -9,662.47% (higher).

CROIC

236.59 %

YoY

-9,662.47%

Last updated:

Cash Return on Invested Capital (CROIC) of Hunan Jingfeng Pharmaceutical Co is 2025 236.59 % . Cash Return on Invested Capital (CROIC) of Hunan Jingfeng Pharmaceutical Co was 2024 -2.47 % . It decreases by -9,662.47% higher compared to the previous year.

The Hunan Jingfeng Pharmaceutical Co CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
4.23 CNY
Jan 1, 2019
-2.36 CNY
Jan 1, 2020
-18.92 CNY
Jan 1, 2021
7.26 CNY
Jan 1, 2022
14.13 CNY
Jan 1, 2023
4.53 CNY
Jan 1, 2024
-2.47 CNY
Jan 1, 2025
236.59 CNY
The Hunan Jingfeng Pharmaceutical Co CROIC history
YEARCROICYoY
236.59 %-9,662.47%
-2.47 %-154.65%
4.53 %-67.96%
14.13 %+94.50%
7.26 %-138.39%
-18.92 %+702.10%
-2.36 %-155.80%
4.23 %-216.66%
-3.62 %-34.12%
-5.50 %+19.86%
-4.59 %-166.11%
6.94 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Hunan Jingfeng Pharmaceutical Co Stock analysis

What does Hunan Jingfeng Pharmaceutical Co do? Hunan Jingfeng Pharmaceutical Co., Ltd. generates revenue through the research, development, manufacture, and sale of chemical and biological drugs. Its main product categories include cardio and cerebrovascular drugs, antihypertensive and hypolipidemic drugs, orthopedic drugs, anti-tumor products, endocrine drugs, digestive system drugs, antiviral drugs, and anti-infective drugs. The company distributes these products domestically and also engages in commodity import and export trading, business management and consulting, and medical technology consulting services. Sales are primarily directed at the domestic market with no mention of international distribution channels. The firm's revenue streams are derived from pharmaceutical sales, particularly in cardiovascular, oncology, and infectious disease treatments, alongside ancillary services such as medical technology consulting. The domestic market remains the sole focus for product distribution, with no indication of export-oriented sales. The company's operations are centered on drug manufacturing and related consulting services, targeting healthcare providers and domestic consumers through established distribution networks. Hunan Jingfeng Pharmaceutical's business model emphasizes product diversity across multiple therapeutic areas, including cardiovascular, oncology, and infectious diseases. The company's revenue is driven by both direct pharmaceutical sales and ancillary consulting services, with all activities confined to the domestic market. The absence of international operations or export-focused strategies is consistent with the business description provided. Hunan Jingfeng Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hunan Jingfeng Pharmaceutical Co stock

Cash Return on Invested Capital (CROIC) of Hunan Jingfeng Pharmaceutical Co is 236.59 % in 2025.

Cash Return on Invested Capital (CROIC) of Hunan Jingfeng Pharmaceutical Co changed from -2.47 % to 236.59 %, representing a -9,662.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Hunan Jingfeng Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Hunan Jingfeng Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Hunan Jingfeng Pharmaceutical Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Hunan Jingfeng Pharmaceutical Co